Form 4: Cabaletta Bio Executive Granted Stock Options

Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., was granted stock options for 130,000 shares on March 1, 2024, according to a Form 4 filing.

Summary

• Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Binder on March 1, 2024.
• The options are for 130,000 shares of Cabaletta Bio's common stock at an exercise price of $23.97 per share.
• The options vest over time, with 25% vesting on March 1, 2025, and the remainder vesting in twelve substantially equal quarterly installments thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive indicator.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The vesting schedule suggests a long-term commitment from the executive to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to practices at companies like Amgen, Gilead, and Biogen.
• The vesting schedule is typical, aligning with industry norms for incentivizing long-term performance.

Key Dates